Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in MMR Deficient or POLE Mutated mCRC
NCT03150706Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- May 2017
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in metastatic colorectal cancer (mCRC), sponsored by Asan Medical Center. Primary endpoints: CT (or MRI) scans of evaluable/measurable lesions by RECIST 1.1 at 6 weeks, Serum CEA at 6 weeks and 2 more. Status: unknown.
02
Drugs
avelumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03150706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150706.